GE HeathCare has FDA approval and launches Invenia ABUS imaging technology to detect Breast Cancer.
GE Healthcare announced FDA approval and the U.S. launch of their new breast imaging technology, the Invenia ABUS, proven to help clinicians find 35.7% more cancers in women with dense breasts than mammograms alone. GE Healthcare will unveil the first Invenia ABUS installations with Fairfax Radiological Consultants (FRC) just outside of Washington, D.C., and Phelps Memorial Hospital in Westchester, NY, whose healthcare providers are now able to offer women with dense breast tissue an efficient, comfortable and non-ionizing screening solution.
Approximately 40% of American women have dense breasts. Having dense breasts can increase a woman�s risk to develop cancer by 4-6 times. Mammography may miss cancers in dense breasts.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins